New hope for myelofibrosis patients: experimental drug TQ05105 enters phase 2 trial

NCT ID NCT07551427

Recruiting now Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This study tests an experimental drug, TQ05105, in 51 adults with intermediate or high-risk myelofibrosis, a serious bone marrow disease. The drug is for patients whose previous treatment (JAK inhibitors) stopped working or caused side effects. The main goal is to see if the drug can shrink an enlarged spleen by at least 35% after 24 weeks of treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS

Contacts and locations

Locations

Affiliated Hospital of Chengde Medical College
RECRUITING

Chengde, Hebei, 067000, China
Cangzhou People's Hospital rovince
RECRUITING

Cangzhou, Hebei, 061014, China
Chinese Academy of Medical Sciences Hematology Hospital
RECRUITING

Tianjin, Tianjin Municipality, 301617, China
Fujian Medical University Union Hospital
RECRUITING

Fuzhou, Fujian, 350001, China
Guangzhou First Municipal People's Hospital
RECRUITING

Guangzhou, Guangdong, 510180, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450000, China
Heping Hospital Affiliated To Changzhi Medical College
RECRUITING

Changzhi, Shanxi, 046000, China
Jiangsu Provincial Hospital of Traditional Chinese Medicine
RECRUITING

Nanjing, Jiangsu, 210029, China
Nanjing Drum Tower Hospital
RECRUITING

Nanjin, Jiangsu, 210000, China
Shanghai Sixth People's Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200233, China
Shengjing Hospital Affiliated to China Medical University
RECRUITING

Shenyang, Liaoning, 110000, China
Sichuan Provincial People's Hospital
RECRUITING

Chengdu, Sichuan, 610000, China
The First Affiliated Hospital of Air Force Medical University
RECRUITING

Xi'an, Shaanxi, 710000, China
The First Affiliated Hospital of Guangxi Medical University
RECRUITING

Nanning, Guangxi, 530000, China
The First Affiliated Hospital of University of Science and Technology of China
RECRUITING

Hefei, Anhui, 230001, China
The First Affiliated Hospital of Xi'an Jiaotong University
RECRUITING

Xi'an, Shaanxi, 710000, China
The First Affiliated Hospital of Xinjiang Medical University
RECRUITING

Ürümqi, Xinjiang, 830011, China
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310003, China
The First Hospital of Jilin University
RECRUITING

Changchun, Jilin, 130021, China
The Second Hospital of Hebei Medical University
RECRUITING

Shijiazhuang, Hebei, 050000, China
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
RECRUITING

Wuhan, Hubei, 430071, China
Union Hospital Tongji College Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430071, China
Xingtai People's Hospital
RECRUITING

Xingtai, Hebei, 054000, China
Zhuzhou Central Hospital
RECRUITING

Zhuzhou, Hunan, 412000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.